However, GLP1RA and GLP1R/GIPR dual agonists, approved for the treatment of type 2 diabetes and more latterly obesity, have also shown efficacy for neurodegenerative and inflammatory disease states7. Here, GIPR is linked to obesity due to melanocortin 4 receptor deficiency.